Persistent Atrial Fibrillation (AF) APAC (Asia Pacific) Observational Study

Terminated

• Conditions: Persistent Atrial Fibrillation
• Interventions: Device: TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)

• Registration Number: NCT04244396
• Lead Sponsor: Abbott Medical Devices

Brief Summary

The objective of this clinical trial is to collect safety and effectiveness data for the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE) in the APAC patient population for the treatment of drug refractory, symptomatic persistent atrial fibrillation when following standard electrophysiology mapping and radiofrequency (RF) ablation procedures.

Detailed Description

The PerAF APAC trial is a prospective, single arm, non-randomized, observational, post-market clinical investigation. Approximately 100 subjects will be enrolled at up to 15 sites in South Korea, Singapore, Hong Kong, Taiwan, and India. Centers in other countries within APAC may be approached for participation in the clinical investigation as needed. Subjects will be followed for 15-months after their initial ablation procedure. The primary effectiveness and safety endpoints will be evaluated through 15-months. A core lab will independently assess AF/Atrial Flutter (AFL)/(Atrial tachycardia (AT) recurrence via Holter monitoring at the 6-month and 15-month follow-up visits. All serious adverse events (SAEs) will be independently adjudicated by qualified physicians not participating in the trial

Study Timeline

• Study First Submitted: 2020-01-24
• Study First Submitted QC: 2020-01-24
• Study First Posted: 2020-01-28
• Study Start: 2020-02-25
• Primary Completion: 2022-11-30
• Study Completion: 2022-11-30
• Status Verified: 2023-11
• Results First Submitted: 2023-11-08
• Results First Submitted QC: 2023-11-08
• Last Update Submitted: 2023-11-08
• Results First Posted: 2024-04-19
• Last Update Posted: 2024-04-19

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 82

Inclusion Criteria

1. Signed informed consent

2. Documented symptomatic persistent AF, defined as continuous AF sustained >7-days but <1 year documented by:

   1. Physician's note AND one of the following:
   2. 24-hr Holter showing continuous AF within 90-days of the procedure OR
   3. 2 ECGs (from any form of rhythm monitoring) showing continuous AF, taken at least 7-days apart

3. Refractory or intolerant to at least one Class I or III antiarrhythmic drug (AAD) as evidenced by recurrent symptomatic AF Note: Intolerant = unable, unwilling, or refusal to take AADs

4. ≥18 years of age

5. Able and willing to complete all pre-, post-, and follow-up testing and requirements

Exclusion Criteria

1. Continuous AF >12 months (longstanding persistent AF)
2. Previous left atrial (LA) surgical or catheter ablation for AF
3. Any cardiac procedure within 90-days prior to initial procedure (Diagnostic procedures with no intervention are not considered a surgical or percutaneous surgical procedure)
4. Coronary artery bypass graft (CABG) surgery within 6-months (180-days) prior to initial procedure
5. Valvular cardiac surgical/percutaneous procedure (i.e. ventriculotomy, valve repair or replacement and/or presence of a prosthetic or mechanical valve)
6. Any carotid stenting or endarterectomy
7. Documented or known left atrial thrombus on imaging
8. Left atrial (LA) diameter >50 mm (parasternal long axis view or by CT)
9. Left Ventricular Ejection Fraction (LVEF) <40%
10. Unable to take anticoagulation medication due to contraindication or intolerance
11. History of blood clotting or bleeding abnormalities
12. Myocardial Infarction (MI), acute coronary syndrome, Percutaneous coronary intervention (PCI) within the 3-months (90-days) prior to the initial procedure
13. Documented thromboembolic event (including TIA) within 12-months (365 days) prior to the initial procedure
14. Rheumatic heart disease
15. Uncontrolled heart failure or New York Heart Association (NYHA) Class III or IV
16. Severe mitral regurgitation (regurgitant volume ≥ 60 mL/beat, regurgitant fraction ≥ 50%, and/or effective regurgitant orifice area ≥ 0.40cm2)
17. Awaiting cardiac transplantation or other cardiac surgery within 12-months (365 days) following the initial ablation procedure
18. Unstable angina at the time of the initial procedure
19. Acute illness or active systemic infection or sepsis
20. AF secondary to electrolyte imbalance, thyroid disease, acute alcohol intoxication, major surgical procedure in the preceding 3-months, or other reversible or non-cardiac cause
21. Diagnosed atrial myxoma
22. Presence of implanted implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy-defibrillator (CRT-D)
23. Significant pulmonary disease, (e.g., restrictive pulmonary disease, constrictive or chronic obstructive pulmonary disease) or any other disease or malfunction of the lungs or respiratory system that produces chronic symptoms
24. Significant congenital anomaly or other anatomic or comorbid medical problem that in the opinion of the investigator would preclude enrollment in this study or compliance with the follow-up requirements or impact the scientific soundness of the clinical trial results
25. Pregnant or nursing subjects and those who plan pregnancy during the clinical investigation follow-up period
26. Enrollment in an investigational study evaluating another device, biologic, or drug that may interfere with this clinical investigation at the time of the initial procedure or within 30 days prior to the initial procedure
27. Presence of any condition that precludes appropriate vascular access or manipulation of catheter
28. Life expectancy less than 12-months
29. Body mass index >40 kg/m2
30. Known sensitivity to contrast media (if needed during the procedure) that cannot be controlled with pre-medication
31. Renal failure requiring dialysis
32. Presence of other medical, social, or psychological conditions that, in the investigator's opinion, could limit the subject's ability to participate in the clinical investigation or to comply with follow-up requirements, or impact the scientific soundness of the clinical investigation results
33. History of atriotomy or ventriotomy
34. Implanted left atrial appendage occlusion device

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Drug refractory, symptomatic persistent atrial fibrillation	TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™ (TactiCath SE)	Asian population

Primary Outcome Measures

Name	Time	Method
Rate of Device and/or Procedure-related Serious Adverse Events	Through 7-days	device and/or procedure-related serious adverse events are pre-defined as below with onset within 7-days of any ablation procedure that uses the TactiCath SE catheter (initial or repeat procedure performed ≤180 days of initial procedure); * Atrioesophageal fistula - assessed through 15 months; * Cardiac tamponade/perforation - assessed through 15 months; * Death; * Heart block; * Myocardial infarction (MI); * Pericarditis - pleuritic symptoms \>7 days and/or requires hospitalization \>24 hrs for reasons other than observational purposes only; * Phrenic nerve injury resulting in diaphragmatic paralysis; * Pneumothorax; * Pulmonary edema (respiratory insufficiency); * Pulmonary vein stenosis - assessed through 15 months; * Stroke/cerebrovascular accident; * Thromboembolism; * Transient ischemic attack; * Vascular access complications (including major bleeding events)

Trial Locations

Locations (9)

Asan Medical Centre; 🇰🇷 Soeul, Korea, Republic of

Sejong Hospital; 🇰🇷 Bucheon, Korea, Republic of

Prince of Wales Hospital; 🇭🇰 Hong Kong, Hong Kong

Severance Hospital, Yonsei University Health System; 🇰🇷 Seoul, Korea, Republic of

National University Hospital; 🇸🇬 Singapore, Singapore

Phramongkutklao Hospital; 🇹🇭 Bangkok, Thailand

National Heart Centre Singapore; 🇸🇬 Singapore, Singapore

Kaohsiung Chang Gung Memorial Hospital; 🇨🇳 Kaohsiung, Taiwan

Taipei Veterans General Hospital; 🇨🇳 Taipei, Taiwan